APA (7th ed.) Citation

PM, C., HD, C., SF, B., EM, S., A, K., V, H., . . . RC, D. (2016). The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. Clinical pharmacology and therapeutics, 100(3), 275. https://doi.org/10.1002/cpt.390

Chicago Style (17th ed.) Citation

PM, Coplan, Chilcoat HD, Butler SF, Sellers EM, Kadakia A, Harikrishnan V, Haddox JD, and Dart RC. "The Effect of an Abuse-deterrent Opioid Formulation (OxyContin) on Opioid Abuse-related Outcomes in the Postmarketing Setting." Clinical Pharmacology and Therapeutics 100, no. 3 (2016): 275. https://doi.org/10.1002/cpt.390.

MLA (9th ed.) Citation

PM, Coplan, et al. "The Effect of an Abuse-deterrent Opioid Formulation (OxyContin) on Opioid Abuse-related Outcomes in the Postmarketing Setting." Clinical Pharmacology and Therapeutics, vol. 100, no. 3, 2016, p. 275, https://doi.org/10.1002/cpt.390.